Nexien Biopharma Inc (NXEN) 收益

Nexien BioPharma, Inc. engages in the development and commercialization of Food and Drug Administration-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company is headquartered in Glendale, Colorado. The company went IPO on 2001-07-11. The firm is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. The firm is utilizing cannabinoids as the active pharmaceutical ingredients to develop synthetic pharmaceuticals in strict accordance with the U.S. FDA pre-clinical and clinical pathways. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The firm's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.